Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age and metabolic disorder in which patients will benefit for early recognition and treatment. The prevalence of PCOS varies between 5% and 10% of all women. Polycystic ovary syndrome is clinically characterized by chronic anovulation, menstrual irregularities, infertility and obesity in combination with some evidence of androgen excess such as hirsutism, acne and increased serum androgen concentrations. The fundamental pathophysiologic defect still remains unknown. PCOS appears to be a heterogeneous disorder in which ovarian, and possibly adrenal androgen excess is present along with varying degrees of gonadotropic and metabolic abnormalities.Additionally insulin resistance, hyperinsulinism, type II Diabetes Mellitus, endometrial carcinoma, dyslipidemia and psychosocial dysfunction are presented as other clinical consequences associated with PCOS.